Jaguar Health Granted Extension Until August 13, 2024, To Regain Compliance With Nasdaq's Bid Price Requirement
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health, Inc. has been granted an extension until August 13, 2024, by Nasdaq to meet the $1.00 bid price requirement for continued listing. The company is also awaiting top line results from its Phase 3 OnTarget trial of crofelemer for the preventative treatment of cancer therapy-related diarrhea.
April 08, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health, Inc. received an extension from Nasdaq to regain compliance with the bid price requirement and is awaiting results from a pivotal Phase 3 trial.
The extension from Nasdaq provides Jaguar Health with additional time to meet the listing requirements, potentially reducing the immediate risk of delisting. This, combined with the anticipation of positive results from the Phase 3 trial, could lead to increased investor confidence and a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100